After the original identification of canine parvovirus (CPV) type 2 (CPV-2) in 1978, new antigenic variants such as CPV-2a, CPV-2b and CPV-2c have become widespread in the most countries. In this study, the genetic analysis of canine parvovirus was investigated in a total of 13 CPV vaccines, which have been licensed in Korea since late 1980s, and a field isolate of CPV from a dog with CPV infection clinical symptom. The partial VP2 gene of CPV was amplified and sequenced from 13 vaccine strains and one field isolate. The results showed that of the 13 vaccine strains, 10 strains belong to the CPV-2, 2 strains to CPV-2b, the remaining and one isolate to CPV-2a type, respectively. Several mutations of amino acids were detected at residues of the critical region of the commercial vaccine strains. These data suggest that new type of vaccines containing CPV-2a or CPV-2b/2c type may be required for the better prevention of new CPV infection in dog population in Korea, because CPV-2 contained in most licensed vaccines has been replaced by antigenic variants designated CPV-2a or CPV-2b/c in the worldwide dog population.

A total of 128 faecal samples of dogs suspected for canine parvovirus infection were examined by Haemagglutination (HA) and Haemagglutination inhibition (HI) tests. The prevalence of canine parvovirus infection was 45.30% (58/128) and the age wise maximum (70.20%) prevalence was found in dogs upto 6 month. The breed wise maximum (56.90%) prevalence was in Non-descript dogs and sex wise prevalence revealed no significant difference in male (45.9%) and female (43.3%).

Canine parvovirus (CPV) is an emerged pathogen in dogs, first isolated in 1978 in the USA. The original 1978 strain was designated CPV type 2 (CPV-2). However, analysis of CPV isolates in the USA by restriction enzymes and monoclonal antibodies have shown that around the year 1979 a CPV variant strain, designated CPV type 2a (CPV-2a), became widespread. Subsequently, a new antigenic strain, designated CPV type 2b (CPV-2b), was also observed by analysis of CPV isolates from various parts of the world, although the proportion of each strains was different between countries. In this study, the Haemagglutination Inhibition (HI) test with a panel of monoclonal antibodies was used to type canine parvovirus strains in 29 fecal samples collected from symptomatic dogs from 1980 to 1986 and from 1990 to 1995. The results showed a strong predominance of the antigenic type 2a indicating that the CPV epizooty in Brazil followed the same pattern observed in European and Asian countries. | O Parvovírus Canino (CPV) é um patógeno emergente em cães, isolado pela primeira vez em 1978, nos Estados Unidos. A amostra original de 1978 foi designada CPV tipo 2 (CPV-2). Entretanto, análises de isolados de CPV dos Estados Unidos, por enzimas de restrição e anticorpos monoclonais demonstraram que cerca de 1979, uma amostra variante, designada CPV tipo 2a (CPV-2a) tornou-se prevalente. Subseqüentemente, uma nova amostra antigênica, designada CPV tipo 2b (CPV-2b) também foi observada por análises de isolados de CPV de várias partes do mundo, embora a proporção fosse diferente entre os países. Nesse estudo, foi utilizado o teste de Inibição da Hemaglutinação (HI) com um painel de anticorpos monoclonais para a tipagem de 29 amostras fecais de parvovirus canino, coletadas de cães sintomáticos de 1980 a 1986 e de 1990 a 1995. Os resultados indicaram uma forte predominância do tipo antigênico 2a indicando que a epizootia de CPV no Brasil seguiu o mesmo padrão observados na Europa e países Asiáticos.